Protara Therapeutics (TARA) Earnings Call Presentation

TARA-002 Product Characteristics - TARA-002 is a lyophilized, inactivated Group A Streptococcus pyogenes [8] - TARA-002 is an investigational, genetically distinct strain of Streptococcus pyogenes that is inactivated while retaining its immune-stimulating properties [10] - TARA-002 activates Th1 Immune Cascade [12] Clinical Trial Results in BCG-Unresponsive Patients - TARA-002 monotherapy demonstrates a 100% complete response rate at any time in BCG-unresponsive participants [14] - Specifically, 5 out of 5 (100%) BCG-unresponsive patients with CIS only achieved a high-grade complete response at any time [15] - At Month 6, 5 out of 5 (100%) BCG-unresponsive patients with CIS only achieved a high-grade complete response [15] - At Month 12, 2 out of 3 (66.7%) BCG-unresponsive patients with CIS only achieved a high-grade complete response [15] Clinical Trial Results in BCG-Naïve Patients - TARA-002 monotherapy demonstrates a 76.2% complete response rate at any time in BCG-naïve participants [22, 23] - Specifically, 10 out of 11 (90.9%) BCG-naïve patients with CIS only achieved a high-grade complete response at any time [23] - At Month 6, 5 out of 6 (83.3%) BCG-naïve patients with CIS only achieved a high-grade complete response [23] - At Month 12, 3 out of 5 (60.0%) BCG-naïve patients with CIS only achieved a high-grade complete response [23] Safety Profile - Across both BCG-unresponsive and BCG-naïve patients (N=43), 74% experienced any grade of treatment-emergent adverse events (TEAEs) [25] - 30% of participants experienced related TEAEs [25] - No Grade 4/5 treatment-related adverse events were observed [7, 25]